Table 1.
Characteristics of β‐Blocker‐Treated Participants in PEAR and PEAR‐2
| Characteristics | PEAR Atenolol Monotherapy (N=374) | PEAR Atenolol Add‐on (N=325) | PEAR‐2 Metoprolol Monotherapy (N=368) | |||
|---|---|---|---|---|---|---|
| White (n=228) | Black (n=146) | White (n=198) | Black (n=127) | White (n=200) | Black (n=168) | |
| Age, mean (SD) y | 49.5±9.5 | 47.2±8.5 | 49.9±9.5 | 47.4±8.8 | 51.0±9.0 | 50.0±9.2 |
| Women, N (%) | 109 (47.3) | 107 (73.2) | 91 (45.9) | 92 (77.3) | 110 (55.0) | 89 (53.0) |
| BMI, mean (SD) kg×m−2 | 30.3±5.6 | 31.6±6.3 | 30.3±4.9 | 31.5±5.4 | 30.8±5.1 | 30.8±5.2 |
| Pretreatment HR, mean (SD) bpm | 76.5±9.2 | 79.9±9.2 | 77.8±9.7 | 81.2±9.6 | 77.7±9.6 | 79.8±9.5 |
| Change in HR, mean (SD) bpm | −12.8±5.5 | −11.0±6.8 | −13.4±6.0 | −11.1±7.4 | −12.3±7.2 | −11.2±7.0 |
BMI indicates body mass index; bpm, beats per minute; HR, heart rate; PEAR, Pharmacogenomic Evaluation of Antihypertensive Responses.